About NITD

NITD fighting infectious diseases including dengue, malaria and tuberculosis

The Novartis Institute for Tropical Diseases (NITD) is dedicated to finding new medicines to treat neglected, infectious diseases. A small-molecule drug discovery research institute, NITD combines the drug-discovery expertise and cutting-edge technology of Novartis to fight infectious tropical diseases.

Currently, it addresses:

Dengue

Tuberculosis

Malaria

In developing countries where these diseases are endemic, Novartis will make treatments readily available and without profit to poor patients.

NITD was set up as a public-private partnership between Novartis and the Singapore Economic Development Board (EDB) in 2002. Since then, it has grown to more than 100 researchers and supporting staff and the following scope of activities:

• Target discovery;
• Screen development;
• Compound optimization;
• Preclinical development;
• Proof-of-Concept clinical trials

NITD is dependent on the early formation of global partnerships. We work with organizations on early research activities, such as target identification and high-throughput screening, and later stages of drug development and patient outreach.

Learn more about career opportunities at NITD

Visit the NITD newsroom